About Royalty Pharma plc

Royalty Pharma plc, founded in 1996, pioneered the pharmaceutical royalty investment model and has built the industry's largest and most diversified portfolio of pharmaceutical royalty interests. The company provides non-dilutive capital to biopharmaceutical companies, academic institutions, and inventors in exchange for royalty streams on approved and development-stage therapies. RPRX stock price reflects the company's unique position in healthcare finance with a portfolio generating predictable cash flows.

Led by founder and CEO Pablo Legorreta, Royalty Pharma benefits from visionary leadership that created and scaled the pharmaceutical royalty asset class. The management team's deep expertise in evaluating pharmaceutical assets and structuring transactions has enabled consistent value creation through cycles. Leadership's disciplined approach to capital deployment and portfolio construction has been instrumental in building a resilient business model that supports RPRX stock price stability and growth.

Royalty Pharma operates by acquiring royalty interests in pharmaceutical products, collecting royalty payments as drugs generate sales, and reinvesting capital into new opportunities. The company's portfolio includes royalties on many of the world's leading therapies across multiple therapeutic areas. With an attractive business model offering high margins and capital-light operations, exposure to pharmaceutical innovation without development risk, and opportunities to deploy capital at attractive returns as funding needs in biopharma remain strong, RPRX offers investors a differentiated way to invest in healthcare with lower risk than traditional biopharmaceutical companies while benefiting from sector growth.